Nutrition
Intermittent fasting
Intermittent fasting bundles several distinct regimens — time-restricted eating, alternate-day fasting, 5:2 — under one label. The most popular form, daily time-restriction, has now been tested directly against ordinary meal timing, with results that undercut its strongest popular claim.
Quick verdict
In the TREAT randomised trial, 16:8 time-restricted eating produced no significant weight-loss advantage over three structured meals a day. Fasting regimens can still help some people eat less; the evidence that the timing itself does metabolic magic is weak.
The assessment
Claim by claim
Each claim is graded on its own evidence. A grade for one claim says nothing about the others.
| Claim | What was measured | Evidence |
|---|---|---|
| Extends human lifespan | Lifespan | Insufficient |
| Time-restricted eating produces greater weight loss than ordinary meal timing | Disease outcome | Against |
Extends human lifespan
Insufficient evidenceOutcome measured: Lifespan — Death from any cause was measured.
No human study has measured whether any fasting regimen extends lifespan.
Why this grade — the appraisal in full
Too little credible research exists to judge the claim either way.
- Available research. No usable studies are linked to this claim.
Limitations. Extrapolated from animal fasting research and short-term human metabolic studies.
Time-restricted eating produces greater weight loss than ordinary meal timing
Evidence against the claimOutcome measured: Disease outcome — A diagnosed condition or clinical event was measured.
TREAT randomised 116 adults with overweight or obesity to 16:8 time-restricted eating or three structured meals for 12 weeks. Weight loss did not differ significantly between groups.
Why this grade — the appraisal in full
Well-conducted human research indicates the claimed effect does not occur, or is too small to matter.
- Strongest study design. Randomised controlled trial with 116 participants.
- Human research volume. 1 human study, 116 participants in total.
- What was measured. 1 human study measured a clinical or functional outcome rather than a laboratory marker alone.
- Replication. The supporting result has not been independently replicated in humans.
- Study duration. Longest human study ran 12 weeks.
Limitations. One 12-week trial of one regimen; longer trials and other schedules could differ. But the popular claim of inherent superiority is currently unsupported by direct test.
| Study | Design | Population | Finding |
|---|---|---|---|
| [1]Effects of Time-Restricted Eating on Weight Loss and Other Metabolic Parameters …JAMA internal medicine · 2020 · PMID 32986097 | Randomised controlled trialHuman | 116 participantsParticipants with a diagnosed condition | Found no effectTREAT: 16:8 TRE vs consistent meal timing; no significant weight-loss difference. |
Human evidence
1 study in people.
- [1]Randomised controlled trial · 116 participants
Animal and laboratory evidence
Shown separately, and never used to support a human claim.
No preclinical study is currently linked on this page.
Before anything else
Safety and interactions
Unsuitable for people with a history of eating disorders, insulin-treated diabetes without medical supervision, pregnancy, and some medication schedules. The TREAT trial also flagged a signal of lean-mass loss worth watching.
The ledger
Grade history
No grade on this page has changed since tracking began. When one moves — a new trial, a retraction, a corrected appraisal — the change is detected automatically and recorded on the public ledger.
Falsifiability
What would change our view
Trials showing consistent benefits of fasting regimens against calorie-matched controls — isolating timing from the reduction in intake it often causes.
Check everything
Sources
Every citation links to its PubMed record. Bibliographic details are retrieved from PubMed, not written by us.
- [1]Effects of Time-Restricted Eating on Weight Loss and Other Metabolic Parameters in Women and Men With Overweight and Obesity: The TREAT Randomized Clinical Trial Lowe DA et al.. JAMA internal medicine. 2020. PMID 32986097 · doi:10.1001/jamainternmed.2020.4153